Date(s) - 27/03/2019
12:30 pm - 2:30 pm
Radisson Blu Plaza Hotel Sydney
Meet ASX listed companies, learn what makes their business compelling, ask their CEOs and executives the questions you want, to get the leading edge, make better-informed decisions and learn about market opportunities.
The Finance News Network and its event partner, preeminent investment house Shaw and Partners, run regular Investor Events that unite companies, investors and stockbrokers.
To keep your finger on the pulse and stay abreast of opportunities, secure your seat at our next event. Register below, bookings are essential.
A short update on the current state of equity markets will also be provided at the event by our event partner, preeminent investment house Shaw and Partners.
APIAM Animal Health Limited (ASX:AHX)
Apiam Animal Health is comprised of Australia’s leading rural veterinary practices. Apiam Animal Health incorporates over 100 highly experienced, industry leading veterinarians with expertise across the pig, dairy, feedlot, sheep, equine and companion animal sectors. Apiam Animal Health is fully vertically integrated, including having veterinary wholesale, warehousing, logistics, and other ancillary services.
Brickworks Limited (ASX:BKW)
Brickworks Limited is a dynamic and innovative group of Australian-owned companies. Our main business is the manufacture and distribution of clay and concrete products, property development and realisation, and investments. We operate in all states throughout Australia and in New Zealand.
Collection House Limited (ASX:CLH)
Collection House Limited (the Group) is a leading Australasian receivables management company, providing organisations and individuals with world-class solutions in credit management, collections and customer care.
Founded in 1994 and listed on the Australian Securities Exchange in 2000, the Group is made up of a number of brands offering a range of professional, ethical and effective products and services.
Neuren Pharmaceuticals Limited (ASX:NEU)
Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders.
Neuren’s strategy emphasises product development opportunities with five crucial attributes: solid scientific rationale, significant unmet medical need, compelling market opportunity, favourable regulatory treatment with a clear path to approval, and potential for development for additional conditions.
Neuren’s lead product trofinetide (also known as NNZ-2566) is licensed to ACADIA Pharmaceuticals for North America, with Neuren retaining all rights outside North America. Trofinetide has completed Phase 2 development for Rett syndrome and is in Phase 2 development for Fragile X syndrome, moderate to severe Traumatic Brain Injury (TBI) and Concussion. Neuren has conducted double-blind placebo-controlled Phase 2 trials in Rett syndrome and Fragile X syndrome, which both demonstrated clinical benefit from treatment with trofinetide.
more to come…